|
1
|
Rivera F, Lopez-Tarruella S, Vega-Villegas
MA and Salcedo M: Treatment of advanced pancreatic cancer: from
gemcitabine single agent to combinations and targeted therapy.
Cancer Treat Rev. 35:335–339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
3
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
4
|
Burris HA, Moore MJ, Andersen J, Green MR,
et al: Improvements in survival and clinical benefit with
gemcitabine as first-line therapy for patients with advanced
pancreas cancer: a randomized trial. J Clin Oncol. 15:2403–2413.
1997.PubMed/NCBI
|
|
5
|
Yu C, Zhang X, Sun G, Guo X, et al: RNA
interference-mediated silencing of the polo-like kinase 1 gene
enhances chemosensitivity to gemcitabine in pancreatic
adenocarcinoma cells. J Cell Mol Med. 12:2234–2249. 2008.PubMed/NCBI
|
|
6
|
El Maalouf G, Le Tourneau C, Batty GN,
Faivre S and Raymond E: Markers involved in resistance to
cytotoxics and targeted therapeutics in pancreatic cancer. Cancer
Treat Rev. 35:167–174. 2009.PubMed/NCBI
|
|
7
|
Tada M, Arizumi M, Nakai Y, Sasaki T, et
al: Efficacy of gemcitabine for locally advanced pancreatic cancer:
comparsion with 5-fuorouracil-based chemoradiotherapy.
Chemotherapy. 54:302–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Basu S, Ghosh A and Hazra B: Evaluation of
the antibacterial activity of Ventilago madraspatana Gaertn., Rubia
cordifolia Linn and Lantana camara Linn: isolation of emodin and
physcion as active antibacterial agents. Phytother Res. 19:888–894.
2005. View
Article : Google Scholar
|
|
9
|
Manojlovic NT, Solujic S, Sukdolak S, et
al: Antifungal activity of Rubia tinctorum, Rhamnus frangula and
Caloplaca cerina. Fitoterapia. 76:244–246. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alves DS, Perez-Fons L, Estepa A, et al:
Membrane-related effects underlying the biological activity of the
anthraquinones emodin and barbaloin. Biochem Pharmacol. 68:549–561.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mbwambo ZH, Apers S, Moshi MJ, et al:
Anthranoid compounds with antiprotozoal activity from Vismia
orientalis. Planta Med. 70:706–710. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li HL, Chen HL, Li H, et al: Regulatory
effects of emodin on NF-kappaB activation and inflammatory cytokine
expression in RAW 264.7 macrophages. Int J Mol Med. 16:41–47.
2005.PubMed/NCBI
|
|
13
|
Kitano A, Saika S, Yamanaka O, Ikeda K,
Okada Y, et al: Emodin suppression of ocular surface inflammatory
reaction. Invest Ophthalmol Vis Sci. 48:5013–5022. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuo YC, Tsai WJ, Meng HC, Chen WP, et al:
Immune reponses in human mesangial cells regulated by emodin from
Polygonum hypoleucum Ohwi. Life Sci. 68:1271–1286. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai J, Razzak A, Hering J, Saed A, et al:
Feasibility evaluation of emodin (rhubarb extract) as an inhibitor
of pancreatic cancer cell proliferation in vitro. J Parenter
Enteral Nutr. 32:190–196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen H, Wei WT, Guo YF, Liu A, et al:
Enhanced effect of gemcitabine by emodin against pancreatic cancer
in vivo via cytochrome C-regulated apoptosis. Oncol Rep.
25:1253–1261. 2011.PubMed/NCBI
|
|
17
|
Jung HA, Chung HY, Yokozawa T, et al:
Alaternin and emodin with hydroxyl radical inhibitory and/or
scavenging activities and hepatoprotective activity on
tacrine-induced cytotoxicity in HepG2 cells. Arch Pharm Res.
27:947–953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu A, Chen H, Tong H, et al: Emodin
potentiates the antitumor effects of gemcitabine in pancreatic
cancer cells via inhibition of nuclear factor-kappaB. Mol Med Rep.
4:221–227. 2011.PubMed/NCBI
|
|
19
|
Hansen MB, Nielsen SE and Berg K:
Re-examination and further development of a precise and rapid dye
method for measuring cell growth/cell kill. J Immunol Methods.
119:203–210. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hao ZM, Li XH, Qiao TD, Du R, Hong L and
Fan DM: CIAPIN1 confers multidrug resistance by upregulating the
expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol
Ther. 5:261–266. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Banerjee S, Wang Z, Kong D and Sarkar FH:
3,3′-Diindolyl-methane enhances chemosensitivity of multiple
chemotherapeutic agents in pancreatic cancer. Cancer Res.
69:5592–5600. 2009.
|
|
22
|
Gao S, Liu Q, Wang X, Lin B and Zhang S:
Effects of Lewis Y antigen on the gene expression of multiple drug
resistance-associated proteins in human ovarian cancer RMG-I-H
cells. Med Oncol. 27:960–967. 2010. View Article : Google Scholar
|
|
23
|
Wang ZH, Chen H, Guo HC, Tong HF, et al:
Emodin antitumor efficacy by the combination of emodin and
gencitabine against human pancreatic cancer cells via
downregulation of the expression of XIAP in vitro and in vivo. Int
J Oncol. 39:1123–1131. 2011.PubMed/NCBI
|
|
24
|
Wei WT, Chen H, Ni ZL, Liu HB, et al:
Antitumor and apoptosis-promoting properties of emodin, an
anthraquinone derivative from Rheum officinale Baill, against
pancreatic cancer in mice via inhibition of Akt activation. Int J
Oncol. 39:1381–1390. 2011.PubMed/NCBI
|
|
25
|
Wang W, Sun YP, Huang XZ, He M, Chen YY,
et al: Emodin enhances sensitivity of gallbladder cancer cells to
platinum drugs via glutathion depletion and MRP1 downregulation.
Biochem Pharmacol. 79:1134–1140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Liu PS, Mao HL, et al: Emodin
sensitizes paclitaxel-resistant human ovarian cancer cells to
paclitaxel-induced apoptosis in vitro. Oncol Rep.
21:1605–1610. 2009.PubMed/NCBI
|
|
27
|
Leonessa F and Clarke R: ATP binding
cassette transporters and drug resistance in breast cancer. Endocr
Relat Cancer. 10:43–73. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takakuwa O, Oguri T, Ozasa H, Uemura T,
Kasai D, et al: Over-expression of MDR1 in amrubicinol-resistant
lung cancer cells. Cancer Chemother Pharmacol. 68:669–676. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dong Y, Shao S, Hu J and Yang P: Reversal
effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug
resistance in KBv200 cell line. Oral Oncol. 45:991–997. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bentires Alj M, Barbu V, Fillet M, et al:
NF-kappaB transcription factor induces drug resistance through MDR1
expression in cancer cells. Oncogene. 22:90–97. 2003.PubMed/NCBI
|
|
31
|
Chen C, Shen HL, Yang J, Chen QY and Xu
WL: Preventing chemoresistance of human breast cancer cell line,
MCF-7 with celecoxib. J Cancer Res Clin Oncol. 137:9–17. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hannun YA: Apoptosis and the dilemma of
cancer chemotherapy. Blood. 89:1845–1853. 1997.PubMed/NCBI
|
|
33
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qi FH, Inagaki Y, Gao B, Cui X and Xu HL:
Bufalin and cinobufagin induce apoptosis of human hepatocellular
carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer
Sci. 102:951–958. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leger DY, Liagre B and Beneytout JL: Role
of MAPKs and NF-kappaB in diosgenin-induced megakaryocytic
differentiation and subsequent apoptosis in HEL cells. Int J Oncol.
28:201–207. 2006.PubMed/NCBI
|
|
36
|
Bachmeier B, Fichtner I, Killian PH,
Kronski E, et al: Development of resistance towards artesunate in
MDA-MB-231 human breast cancer cells. PLoS One. 6:e205502011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kumar MV, Shirley R, Ma Y and Lewis RW:
Role of genomics-based strategies in overcoming chemotherapeutic
resistance. Curr Pharm Biotechnol. 5:471–480. 2004. View Article : Google Scholar : PubMed/NCBI
|
